Delcath ACHIEVES >$29M Q2 REVENUE, GUIDES FOR $104M-$108M FY 2026
Delcath reported a 20% increase in Q2 2026 revenue driven by HEPZATO procedures; the company raised its full year 2026 revenue guidance to a range of $104 million to $108 million.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day